Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
6 "Meta-analysis"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Type 1 Diabetes
Article image
Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis
Deep Dutta, Ritin Mohindra, Kunal Mahajan, Meha Sharma
Diabetes Metab J. 2023;47(1):72-81.   Published online June 24, 2022
DOI: https://doi.org/10.4093/dmj.2022.0035
  • 5,451 View
  • 256 Download
  • 1 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
No meta-analysis has analysed efficacy and safety of fast-acting aspart insulin (FIAsp) with insulin pump in type 1 diabetes mellitus (T1DM).
Methods
Electronic databases were searched for randomised controlled trials (RCTs) involving T1DM patients on insulin pump receiving FIAsp in intervention arm, and placebo/active comparator insulin in control arm. Primary outcome was to evaluate changes in 1- and 2-hour post-prandial glucose (1hPPG and 2hPPG). Secondary outcomes were to evaluate alterations in percentage time with blood glucose <3.9 mmol/L (hypoglycaemia), time in range (TIR) blood glucose 3.9 to 10 mmol/L, insulin requirements and adverse events.
Results
Data from four RCTs involving 640 patients was analysed. FIAsp use in insulin pump was associated with significantly greater lowering of 1hPPG (mean difference [MD], –1.35 mmol/L; 95% confidence interval [CI], –1.72 to –0.98; P<0.01; I2=63%) and 2hPPG (MD, –1.19 mmol/L; 95% CI, –1.38 to –1.00; P<0.01; I2=0%) as compared to controls. TIR was comparable among groups (MD, 1.06%; 95% CI, –3.84 to 5.96; P=0.67; I2=70%). Duration of blood glucose <3.9 mmol/L was lower in FIAsp group, approaching significance (MD, –0.91%; 95% CI, –1.84 to 0.03; P=0.06; I2=0%). Total hypoglycaemic episodes (risk ratio [RR], 1.35; 95% CI, 0.55 to 3.31; P=0.51; I2=0%), severe hypoglycaemia (RR, 2.26; 95% CI, 0.77 to 6.66; P=0.14), infusion site reactions (RR, 1.35; 95% CI, 0.63 to 2.93; P=0.77; I2=0%), and treatment-emergent adverse events (RR, 1.13; 95% CI, 0.80 to 1.60; P=0.50; I2=0%) were comparable.
Conclusion
FIAsp use in insulin pump is associated with better post-prandial glycaemic control with no increased hypoglycaemia or glycaemic variability.

Citations

Citations to this article as recorded by  
  • Burden and Coping Strategies of Hypoglycemia in People with Diabetes
    Aris Liakos, Thomas Karagiannis, Ioannis Avgerinos, Apostolos Tsapas, Eleni Bekiari
    Current Diabetes Reviews.2024;[Epub]     CrossRef
  • Efficacy and Safety of Ultra-rapid Lispro Insulin in Managing Type-1 and Type-2 Diabetes: A Systematic Review and Meta-Analysis
    Deep Dutta, Lakshmi Nagendra, Saptarshi Bhattacharya, Meha Sharma
    Indian Journal of Endocrinology and Metabolism.2023; 27(6): 467.     CrossRef
Metabolic Risk/Epidemiology
Effect of Different Types of Diagnostic Criteria for Gestational Diabetes Mellitus on Adverse Neonatal Outcomes: A Systematic Review, Meta-Analysis, and Meta-Regression
Fahimeh Ramezani Tehrani, Marzieh Saei Ghare Naz, Razieh Bidhendi-Yarandi, Samira Behboudi-Gandevani
Diabetes Metab J. 2022;46(4):605-619.   Published online March 8, 2022
DOI: https://doi.org/10.4093/dmj.2021.0178
  • 5,739 View
  • 304 Download
  • 8 Web of Science
  • 8 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Evidence supporting various diagnostic criteria for diagnose gestational diabetes mellitus (GDM) are consensus-based, needs for additional evidence related to outcomes. Therefore, the aim of this systematic-review and meta-analysis was to assess the impact of different GDM diagnostic-criteria on the risk of adverse-neonatal-outcomes.
Methods
Electronic databases including Scopus, PubMed, and Web of Sciences were searched to retrieve English original, population-based studies with the universal GDM screening approach, up to January-2020. GDM diagnostic criteria were classified in seven groups and International Association of the Diabetes and Pregnancy Study Groups (IADPSG) was considered as reference one. We used the Mantel–Haenszel method to calculate the pooled odds of events. The possibility of publication bias was examined by Begg’s test.
Results
A total of 55 population-based studies consisting of 1,604,391 pregnant women with GDM and 7,770,855 non-GDM counterparts were included. Results showed that in all diagnostic-criteria subgroups, the risk of adverse neonatal outcomes including macrosomia, hyperbilirubinemia, respiratory distress syndrome, neonatal hypoglycemia, neonatal intensive care unit admission, preterm birth, and birth-trauma were significantly higher than the non-GDM counterparts were significantly higher than non-GDM counterparts. Meta-regression analysis revealed that the magnitude of neonatal risks in all diagnostic-criteria subgroups are similar.
Conclusion
Our results showed that the risk of adverse-neonatal-outcome increased among women with GDM, but the magnitude of risk was not different among those women who were diagnosed through more or less intensive strategies. These findings may help health-care-providers and policy-makers to select the most cost-effective approach for the screening of GDM among pregnant women.

Citations

Citations to this article as recorded by  
  • Hyperglycemia in pregnancy did not worsen the short-term outcomes of very preterm infants: a propensity score matching study
    Ying Li, Wei Shen, Rong Zhang, Jian Mao, Ling Liu, Yan-Mei Chang, Xiu-Zhen Ye, Yin-Ping Qiu, Li Ma, Rui Cheng, Hui Wu, Dong-Mei Chen, Ling Chen, Ping Xu, Hua Mei, San-Nan Wang, Fa-Lin Xu, Rong Ju, Xiao-Mei Tong, Xin-Zhu Lin, Fan Wu
    Frontiers in Pediatrics.2024;[Epub]     CrossRef
  • One-step vs 2-step gestational diabetes mellitus screening and pregnancy outcomes: an updated systematic review and meta-analysis
    Cintia Gomes, Itamar D. Futterman, Olivia Sher, Bracha Gluck, Teresa A. Hillier, Fahimeh Ramezani Tehrani, Nadim Chaarani, Nelli Fisher, Vincenzo Berghella, Rodney A. McLaren
    American Journal of Obstetrics & Gynecology MFM.2024; 6(5): 101346.     CrossRef
  • Diabetesscreening in der Schwangerschaft
    Ute Schäfer-Graf
    Die Gynäkologie.2023; 56(2): 103.     CrossRef
  • One-step versus two-step screening for diagnosis of gestational diabetes mellitus in Iranian population: A randomized community trial
    Fahimeh Ramezani Tehrani, Maryam Rahmati, Farshad Farzadfar, Mehrandokht Abedini, Maryam Farahmand, Farhad Hosseinpanah, Farzad Hadaegh, Farahnaz Torkestani, Majid Valizadeh, Fereidoun Azizi, Samira Behboudi-Gandevani
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Predictors of Neonatal Intensive Care Unit Admission and Adverse Outcomes Related to Gestational Diabetes
    Abdullah M Al-shahrani
    Cureus.2023;[Epub]     CrossRef
  • Positive association between circulating Caveolin-1 and microalbuminuria in overt diabetes mellitus in pregnancy
    Y. Shu, Y. Xiong, Y. Song, S. Jin, X. Bai
    Journal of Endocrinological Investigation.2023; 47(1): 201.     CrossRef
  • Early-to-mid pregnancy sleep and circadian markers in relation to birth outcomes: An epigenetics pilot study
    Erica C. Jansen, Kelvin Pengyuan Zhang, Dana C. Dolinoy, Helen J. Burgess, Louise M. O’Brien, Elizabeth Langen, Naquia Unwala, Jessa Ehlinger, Molly C. Mulcahy, Jaclyn M. Goodrich
    Chronobiology International.2023; 40(9): 1224.     CrossRef
  • Various screening and diagnosis approaches for gestational diabetes mellitus and adverse pregnancy outcomes: a secondary analysis of a randomized non-inferiority field trial
    Fahimeh Ramezani Tehrani, Ali Sheidaei, Maryam Rahmati, Farshad Farzadfar, Mahsa Noroozzadeh, Farhad Hosseinpanah, Mehrandokht Abedini, Farzad Hadaegh, Majid Valizadeh, Farahnaz Torkestani, Davood Khalili, Faegheh Firouzi, Masoud Solaymani-Dodaran, Afshin
    BMJ Open Diabetes Research & Care.2023; 11(6): e003510.     CrossRef
COVID-19
Impact of COVID-19 Lockdown on the Metabolic Control Parameters in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
Ifan Ali Wafa, Nando Reza Pratama, Nurizzah Farahiyah Sofia, Elsha Stephanie Anastasia, Tiffany Konstantin, Maharani Ayuputeri Wijaya, M. Rifqi Wiyono, Lilik Djuari, Hermina Novida
Diabetes Metab J. 2022;46(2):260-272.   Published online March 8, 2022
DOI: https://doi.org/10.4093/dmj.2021.0125
  • 6,364 View
  • 277 Download
  • 11 Web of Science
  • 11 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Abrupt implementation of lockdowns during the coronavirus disease 2019 (COVID-19) pandemic affected the management of diabetes mellitus in patients worldwide. Limited access to health facilities and lifestyle changes potentially affected metabolic parameters in patients at risk. We conducted a meta-analysis to determine any differences in the control of metabolic parameters in patients with diabetes, before and during lockdown.
Methods
We performed searches of five databases. Meta-analyses were carried out using random- or fixed-effect approaches to glycaemic control parameters as the primary outcome: glycosylated hemoglobin (HbA1c), random blood glucose (RBG), fasting blood glucose (FBG), time-in-range (TIR), time-above-range (TAR), time-below-range (TBR). Mean difference (MD), confidence interval (CI), and P value were calculated. Lipid profile was a secondary outcome and is presented as a descriptive analysis.
Results
Twenty-one studies enrolling a total of 3,992 patients with type 1 or type 2 diabetes mellitus (T1DM or T2DM) were included in the study. Patients with T1DM showed a significant improvement of TIR and TAR (MD=3.52% [95% CI, 0.29 to 6.74], I2=76%, P=0.03; MD=–3.36% [95% CI, –6.48 to –0.25], I2=75%, P=0.03), while FBG among patients with T2DM significantly worsened (MD=3.47 mg/dL [95% CI, 1.22 to 5.73], I2=0%, P<0.01). No significant difference was found in HbA1c, RBG, and TBR. Use of continuous glucose monitoring in T1DM facilitated good glycaemic control. Significant deterioration of lipid parameters during lockdown, particularly triglyceride, was observed.
Conclusion
Implementation of lockdowns during the COVID-19 pandemic did not worsen glycaemic control in patients with diabetes. Other metabolic parameters improved during lockdown, though lipid parameters, particularly triglyceride, worsened.

Citations

Citations to this article as recorded by  
  • Disruption of diabetes and hypertension care during the COVID-19 pandemic and recovery approaches in the Latin America and Caribbean region: a scoping review protocol
    Samira Barbara Jabakhanji, Oluwabunmi Ogungbe, Sonia Y Angell, Lawrence Appel, David Byrne, Roopa Mehta, John McCaffrey, Lori Rosman, Edward W Gregg, Kunihiro Matsushita
    BMJ Open.2024; 14(1): e074443.     CrossRef
  • Influence of the COVID-19 pandemic on the achievement of guideline targets for HbA1c, blood pressure, and LDL cholesterol in people with diabetes in Japan
    Shingo Kuwajima, Takahito Itoh, Tatsuya Sato, Shoya Ino, Satoru Shibata, Kouhei Ohno, Hiroyuki Hotta, Tomoaki Matsumoto, Hitoshi Ooiwa, Hirofumi Kubo, Takayuki Miki
    Diabetology International.2024;[Epub]     CrossRef
  • Effect of the SARS-CoV-2 pandemic on metabolic control in patients with type 2 diabetes: a 5-year cohort follow-up managed by a dynamic multidisciplinary team in Northeastern Mexico
    Devany Paola Morales-Rodriguez, Arnulfo González-Cantú, Arnulfo Garza-Silva, Andrea Rivera-Cavazos, Iván Francisco Fernández-Chau, Andrea Belinda Cepeda-Medina, Miguel Angel Sanz-Sánchez, Gerardo Francisco del Rio-Parra, María Angelina Torres-Fuentes, Mig
    Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
  • Glycemic Control in Type 1 Diabetes Mellitus and COVID-19: What We Learned From the Lockdown Experience
    Catarina Almeida, André Ferreira, Daniela Duarte, Ana Filipa Viegas, André Santos, Alexandra Vaz, Edite Nascimento
    Cureus.2023;[Epub]     CrossRef
  • Changes in body weight and glycemic control in association with COVID-19 Shutdown among 23,000 adults with type 2 diabetes
    Emily Panza, Kevin E. Kip, Kripa Venkatakrishnan, Oscar C. Marroquin, Rena R. Wing
    Acta Diabetologica.2023; 60(6): 787.     CrossRef
  • The Impact of a Lockdown for the COVID-19 Pandemic on Seasonal HbA1c Variation in Patients with Type 2 Diabetes
    Yu-Cheng Cheng, Yu-Hsuan Li, Hsiu-Chen Liu, Chiann-Yi Hsu, Wan-Jen Chang, I-Te Lee, Chin-Li Lu
    Life.2023; 13(3): 763.     CrossRef
  • The Impact of Partial Lockdown During COVID-19 Pandemic on Metabolic Control in People with Type 2 Diabetes Mellitus
    Ayşe Zülal TOKAÇ, Tuğde Buse UĞUR, Buse Ecem KURUGÖL, Sevilay ALİGÜLÜ, Osman HAYRAN
    Journal of Biotechnology and Strategic Health Research.2023; 7(1): 67.     CrossRef
  • Retrospective Study on the Impact of COVID-19 Lockdown on Patients with Type 2 Diabetes in Northern Taiwan
    Hsuan Huang, Hsiao-Ling Su, Chih-Hsung Huang, Yi-Hsin Lin
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2539.     CrossRef
  • RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications
    Dan Ke, Zhen Zhang, Jieting Liu, Peijian Chen, Yucen Dai, Xinhai Sun, Yanhui Chu, Luxin Li
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • “Does Physical Exercise Promote Health Benefits for Diabetic Patients during the COVID-19 Pandemic?”: A Systematic Review
    Erivaldo de Souza, Daniela Meneses-Santos, Josué Cruz Santos, Felipe J. Aidar, Carla Roberta de Oliveira Carvalho, Jymmys Lopes dos Santos, Anderson Carlos Marçal
    Sports.2023; 11(10): 192.     CrossRef
  • Impact of National Lockdown From COVID-19 Pandemic in Patients With Type 2 Diabetes: An Observational Study
    Nuntakorn Thongtang, Niracha Chanwimol, Lukana Preechasuk, Varisara Boonyuang, Pinyo Rattanaumpawan, Supawadee Likitmaskul, Apiradee Sriwijitkamol
    Asia Pacific Journal of Public Health.2022; 34(6-7): 708.     CrossRef
Clinical Diabetes & Therapeutics
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials
Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Seung Eun Lee, Woo Je Lee, Joong-Yeol Park, Ye-Jee Kim, Chang Hee Jung, Michael A. Nauck
Diabetes Metab J. 2019;43(4):410-421.   Published online December 27, 2018
DOI: https://doi.org/10.4093/dmj.2018.0070
  • 6,847 View
  • 143 Download
  • 19 Web of Science
  • 20 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Based on reported results of three large cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), we aimed to investigate the overall effect of GLP-1 RAs on major adverse cardiovascular events (MACEs) and to identify subpopulations exhibiting the greatest cardiovascular (CV) benefit.

Methods

Three CVOTs reporting effects of long-acting GLP-1 RAs were included: LEADER (liraglutide), SUSTAIN-6 (semaglutide), and EXSCEL (exenatide once weekly). In all studies, the primary endpoint was three-point MACE, comprising CV death, non-fatal myocardial infarction, and non-fatal stroke. Overall effect estimates were calculated as hazard ratios and 95% confidence intervals (CIs) using the random-effects model; subgroup analyses reported in the original studies were similarly analyzed.

Results

Overall, statistically significant risk reductions in MACE and CV death were observed. Subgroup analysis indicated a significant racial difference with respect to CV benefit (P for interaction <0.001), and more substantial risk reductions were observed in subjects of African origin (relative risk [RR], 0.78; 95% CI, 0.60 to 0.99) and in Asians (RR, 0.35; 95% CI, 0.09 to 1.32). However, post hoc analysis (Bonferroni method) revealed that only Asians exhibited a significantly greater CV benefit from treatment, compared with white subjects (P<0.0001).

Conclusion

Long-acting GLP-1 RAs reduced risks of MACE and CV deaths in high-risk patients with type 2 diabetes mellitus. Our findings of a particularly effective reduction in CV events with GLP-1 RA in Asian populations merits further exploration and dedicated trials in specific populations.

Citations

Citations to this article as recorded by  
  • Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
    Jeonghee Han, Woo Je Lee, Kyu Yeon Hur, Jae Hyoung Cho, Byung Wan Lee, Cheol-Young Park
    Diabetes & Metabolism Journal.2024; 48(3): 418.     CrossRef
  • Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials
    Frederick Berro Rivera, Nathan Ross B. Bantayan, John Paul Aparece, Linnaeus Louisse A. Cruz, John Vincent Magallong, Polyn Luz Pine, Anne Mira Nicca Idian-Javier, Grace Nooriza O. Lumbang, Edgar V. Lerma, Kyla M. Lara-Breitinger, Martha Gulati, Krishnasw
    Journal of Clinical Lipidology.2024;[Epub]     CrossRef
  • A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD‐JPN)
    Tomoaki Morioka, Masakazu Takeuchi, Akichika Ozeki, Masanori Emoto
    Diabetes, Obesity and Metabolism.2024;[Epub]     CrossRef
  • Coronary Artery Disease in South Asian Patients: Cardiovascular Risk Factors, Pathogenesis and Treatments
    Vincenzo Sucato, Giuseppe Coppola, Girolamo Manno, Giuseppe Vadalà, Giuseppina Novo, Egle Corrado, Alfredo Ruggero Galassi
    Current Problems in Cardiology.2023; 48(8): 101228.     CrossRef
  • Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
    Hodaka Yamada, Masashi Yoshida, Shunsuke Funazaki, Jun Morimoto, Shiori Tonezawa, Asuka Takahashi, Shuichi Nagashima, Kimura Masahiko, Otsuka Kiyoshi, Kazuo Hara
    Journal of Cardiovascular Development and Disease.2023; 10(4): 176.     CrossRef
  • Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus
    L. Yu. Khamnueva, L. S. Andreeva
    Problems of Endocrinology.2023; 69(2): 38.     CrossRef
  • Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
    Sian A. Bradley, Kevin J. Spring, Roy G. Beran, Dimitrios Chatzis, Murray C. Killingsworth, Sonu M. M. Bhaskar
    Diabetes/Metabolism Research and Reviews.2022;[Epub]     CrossRef
  • Obesity Pillars Roundtable: Obesity and East Asians
    Harold Edward Bays, Jennifer Ng, Jeffrey Sicat, Michelle Look
    Obesity Pillars.2022; 2: 100011.     CrossRef
  • Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
    Calvin Ke, K. M. Venkat Narayan, Juliana C. N. Chan, Prabhat Jha, Baiju R. Shah
    Nature Reviews Endocrinology.2022; 18(7): 413.     CrossRef
  • Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Timothy M. E. Davis, Anna Giczewska, Yuliya Lokhnygina, Robert J. Mentz, Naveed Sattar, Rury R. Holman
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
    Xiaoling Cai, Linong Ji
    Diabetes Therapy.2021; 12(7): 1861.     CrossRef
  • Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
    Jae-Seung Yun, Seung-Hyun Ko
    Metabolism.2021; 123: 154838.     CrossRef
  • Sex and ethnic differences in the cardiovascular complications of type 2 diabetes
    Jian L. Yeo, Emer M. Brady, Gerry P. McCann, Gaurav S. Gulsin
    Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110342.     CrossRef
  • Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Efficacy and safety of dulaglutide in type 2 diabetes patients in endocrinology clinics of Islamabad, Pakistan
    Matiullah Kamin, SajjadAli Khan, UmarYousaf Raja, Osama Ishtiaq, Asmara Malik, Tejhmal Rehman, MuhammadUmar Wahab
    Indian Journal of Endocrinology and Metabolism.2021; 25(5): 456.     CrossRef
  • Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in South Asians: a Unique Population with a Growing Challenge
    Afreen I. Shariff, Nitya Kumar, William S. Yancy, Leonor Corsino
    Current Diabetes Reports.2020;[Epub]     CrossRef
  • Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
    Christopher S. Wilcox
    Hypertension.2020; 75(4): 894.     CrossRef
  • Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
    Liyun He, Na Yang, Lingling Xu, Fan Ping, Wei Li, Yuxiu Li, Huabing Zhang
    Diabetes Therapy.2020; 11(9): 2121.     CrossRef
  • 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
    Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu, Kuan-Cheng Chang, Kou-Gi Shyu, Jin-Long Huang, Cheng-Dao Tsai, Huei-Fong Hung, Ming-En Liu, Tze-Fan Chao,
    Journal of the Chinese Medical Association.2020; 83(7): 587.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
Clinical Diabetes & Therapeutics
Effectiveness of Exercise Intervention in Reducing Body Weight and Glycosylated Hemoglobin Levels in Patients with Type 2 Diabetes Mellitus in Korea: A Systematic Review and Meta-Analysis
Ji-Eun Jang, Yongin Cho, Byung Wan Lee, Ein-Soon Shin, Sun Hee Lee
Diabetes Metab J. 2019;43(3):302-318.   Published online November 19, 2018
DOI: https://doi.org/10.4093/dmj.2018.0062
  • 5,695 View
  • 98 Download
  • 13 Web of Science
  • 13 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

This study aimed to assess the effectiveness of exercise intervention in reducing body weight and glycosylated hemoglobin (HbA1c) level in patients with type 2 diabetes mellitus (T2DM) in Korea.

Methods

Cochrane, PubMed, Embase, KoreaMed, KMbase, NDSL, KCI, RISS, and DBpia databases were used to search randomized controlled trials and controlled clinical trials that compared exercise with non-exercise intervention among patients with non-insulin-treated T2DM in Korea. The effectiveness of exercise intervention was estimated by the mean difference in body weight changes and HbA1c level. Weighted mean difference (WMD) with its corresponding 95% confidence interval (CI) was used as the effect size. The pooled mean differences of outcomes were calculated using a random-effects model.

Results

We identified 7,692 studies through literature search and selected 23 articles (723 participants). Compared with the control group, exercise intervention (17 studies) was associated with a significant decline in HbA1c level (WMD, −0.58%; 95% CI, −0.89 to −0.27; I2=73%). Although no significant effectiveness on body weight was observed, eight aerobic training studies showed a significant reduction in body weight (WMD, −2.25 kg; 95% CI, −4.36 to −0.13; I2=17%) in the subgroup analysis.

Conclusion

Exercise significantly improves glycemic control; however, it does not significantly reduce body weight. Aerobic training can be beneficial for patients with non-insulin-treated T2DM in Korea.

Citations

Citations to this article as recorded by  
  • Effect of low-volume combined aerobic and resistance high-intensity interval training on vascular health in people with type 2 diabetes: a randomised controlled trial
    Emily R. Cox, Trishan Gajanand, Shelley E. Keating, Matthew D. Hordern, Nicola W. Burton, Daniel J. Green, Joyce S. Ramos, Maximiano V. Ramos, Robert G. Fassett, Stephen V. Cox, Jeff S. Coombes, Tom G. Bailey
    European Journal of Applied Physiology.2024;[Epub]     CrossRef
  • The anti-inflammatory effects of aerobic exercise training in patients with type 2 diabetes: A systematic review and meta-analysis
    Georgia Papagianni, Chrystalla Panayiotou, Michail Vardas, Nikolaos Balaskas, Constantinos Antonopoulos, Dimitrios Tachmatzidis, Triantafyllos Didangelos, Vaia Lambadiari, Nikolaos P.E. Kadoglou
    Cytokine.2023; 164: 156157.     CrossRef
  • Glucose Control in Korean Patients with Type 2 Diabetes Mellitus according to Body Mass Index
    Ye-lim Shin, Heesoh Yoo, Joo Young Hong, Jooeun Kim, Kyung-do Han, Kyu-Na Lee, Yang-Hyun Kim
    Journal of Obesity & Metabolic Syndrome.2023; 32(1): 55.     CrossRef
  • Exercise therapy for diabetes mellitus
    Chaiho Jeong, Tae-Seo Sohn
    Journal of the Korean Medical Association.2023; 66(7): 427.     CrossRef
  • Effects of an evidence‐based nursing intervention on prevention of anxiety and depression in the postpartum period
    Jun Meng, Junying Du, Xiaoli Diao, Yingxia Zou
    Stress and Health.2022; 38(3): 435.     CrossRef
  • Effect of exercise intervention dosage on reducing visceral adipose tissue: a systematic review and network meta-analysis of randomized controlled trials
    Yu-Hsuan Chang, Hui-Ying Yang, Shiow-Ching Shun
    International Journal of Obesity.2021; 45(5): 982.     CrossRef
  • Development and validation of the type 2 diabetes mellitus 10-year risk score prediction models from survey data
    Gregor Stiglic, Fei Wang, Aziz Sheikh, Leona Cilar
    Primary Care Diabetes.2021; 15(4): 699.     CrossRef
  • Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
    Jingxuan Lian, Jianfang Fu
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Exercise Training: The Holistic Approach in Cardiovascular Prevention
    Francesco Giallauria, Teresa Strisciuglio, Gianluigi Cuomo, Anna Di Lorenzo, Andrea D’Angelo, Mario Volpicelli, Raffaele Izzo, Maria Virginia Manzi, Emanuele Barbato, Carmine Morisco
    High Blood Pressure & Cardiovascular Prevention.2021; 28(6): 561.     CrossRef
  • Effect of chronic High Intensity Interval Training on glycosylated haemoglobin in people with type 2 diabetes: a meta-analysis
    María Cristina Arrieta-Leandro, Jessenia Hernández-Elizondo, Judith Jiménez-Díaz
    Human Movement.2021; 24(1): 32.     CrossRef
  • Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
    Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
    Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
  • Factors Influencing Glycemic Control among Type 2 Diabetes Mellitus Patients: The Sixth Korea National Health and Nutrition Examination Survey (2013~2015)
    Mee Ock Gu
    Korean Journal of Adult Nursing.2019; 31(3): 235.     CrossRef
Review
Clinical Diabetes & Therapeutics
The Effectiveness of Green Tea or Green Tea Extract on Insulin Resistance and Glycemic Control in Type 2 Diabetes Mellitus: A Meta-Analysis
Jinyue Yu, Peige Song, Rachel Perry, Chris Penfold, Ashley R. Cooper
Diabetes Metab J. 2017;41(4):251-262.   Published online August 22, 2017
DOI: https://doi.org/10.4093/dmj.2017.41.4.251
  • 8,061 View
  • 116 Download
  • 48 Web of Science
  • 52 Crossref
AbstractAbstract PDFPubReader   

Green tea or green tea extract (GT/GTE) has been demonstrated to reduce insulin resistance and improve glycemic control. However, evidence for this health beneficial effect is inconsistent. This systematic review evaluated the effect of GT/GTE on insulin resistance and glycemic control in people with pre-diabetes/type 2 diabetes mellitus (T2DM). Ovid MEDLINE, Embase, AMED, Web of Science, and the Cochrane Library were searched up to April 2017 for randomised controlled trials of participants with pre-diabetes or T2DM, where the intervention was GT/GTE. Meta-analysis was performed to assess the standardised mean difference (SMD) in biomarkers of insulin resistance and glycemic control between GT/GTE and placebo groups. Six studies (n=382) were pooled into random-effects meta-analysis. Overall, no differences were found between GT/GTE and the placebo for glycosylated hemoglobin (HbA1c: SMD, −0.32; 95% confidence interval [CI], −0.86 to 0.23), homeostatic model assessment for insulin resistance (HOMA-IR: SMD, 0.10; 95% CI, −0.17 to 0.38), fasting insulin (SMD, −0.25; 95% CI, −0.64 to 0.15), and fasting glucose (SMD, −0.10; 95% CI, −0.50 to 0.30). No evidence support the consumption of GT/GTE could reduce the levels of HbA1c, HOMA-IR, fasting insulin, or fasting glucose in people with pre-diabetes/T2DM. However, the studies included were small and of varying quality.

Citations

Citations to this article as recorded by  
  • Is breakfast consumption detrimental, unnecessary, or an opportunity for health promotion? A review of cardiometabolic outcomes and functional food choices
    Heitor O. Santos, Grant M. Tinsley
    Diabetes/Metabolism Research and Reviews.2024;[Epub]     CrossRef
  • A comparison of the effects of green tea and cocoa on glycaemic control and insulin sensitivity in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
    Hind Mesfer S. Alkhudaydi, Jeremy P.E. Spencer
    Nutrition and Healthy Aging.2024; 9(1): 17.     CrossRef
  • Association between green tea intake and digestive system cancer risk in European and East Asian populations: a Mendelian randomization study
    Duorui Nie, Xiaoyu He, Hao Zheng, Deyu Deng, Fanghui He, Ruyi Li, Xiaoting Ni, Shunxiang Li, Fei Xu
    European Journal of Nutrition.2024; 63(4): 1103.     CrossRef
  • From Gut to Glucose: A Comprehensive Review on Functional Foods and Dietary Interventions for Diabetes Management
    Nirali Patel, Susha Dinesh, Sameer Sharma
    Current Diabetes Reviews.2024;[Epub]     CrossRef
  • Anti-atherogenic role of green tea (Camellia sinensis) in South Indian smokers
    Venkateswarlu Reddy Kanu, Swetha Pulakuntla, Gouthami Kuruvalli, Sree Latha Aramgam, Shakeela Begum Marthadu, Padmavathi Pannuru, Ananda Vardhan Hebbani, Padma Priya Dharmavaram Desai, Kameswara Rao Badri, Damodara Reddy Vaddi
    Journal of Ethnopharmacology.2024; 332: 118298.     CrossRef
  • Gut microbiota as a driver of the interindividual variability of cardiometabolic effects from tea polyphenols
    Qiqiong Li, Tom Van de Wiele
    Critical Reviews in Food Science and Nutrition.2023; 63(11): 1500.     CrossRef
  • Recent insights on tea metabolites, their biosynthesis and chemo-preventing effects: A review
    Ramkumar Samynathan, Muthu Thiruvengadam, Shivraj Hariram Nile, Mohammad Ali Shariati, Maksim Rebezov, Raghvendra Kumar Mishra, Baskar Venkidasamy, Sureshkumar Periyasamy, Ill-Min Chung, Mirian Pateiro, José M. Lorenzo
    Critical Reviews in Food Science and Nutrition.2023; 63(18): 3130.     CrossRef
  • Tea's anti‐obesity properties, cardiometabolic health‐promoting potentials, bioactive compounds, and adverse effects: A review focusing on white and green teas
    Behnaz Abiri, Shirin Amini, Mahdi Hejazi, Farhad Hosseinpanah, Afshin Zarghi, Faeze Abbaspour, Majid Valizadeh
    Food Science & Nutrition.2023; 11(10): 5818.     CrossRef
  • An investigation into the potential action of polyphenols against human Islet Amyloid Polypeptide aggregation in type 2 diabetes
    Anns Mahboob, Degiri Kalana Lasanga Senevirathne, Pradipta Paul, Faisal Nabi, Rizwan Hasan Khan, Ali Chaari
    International Journal of Biological Macromolecules.2023; 225: 318.     CrossRef
  • Association between green tea consumption and metabolic syndrome among Korean adults: results from the Health Examinees study
    Hyeonjin Cho, Sunwoo Han, Jiwon Jeong, Hyein Jung, Sangah Shin
    Journal of Nutrition and Health.2023; 56(1): 70.     CrossRef
  • Relevance of Indian traditional tisanes in the management of type 2 diabetes mellitus: A review
    Devi Datt Joshi, Lokesh Deb, Bharat G. Somkuwar, Virendra Singh Rana
    Saudi Pharmaceutical Journal.2023; 31(5): 626.     CrossRef
  • Evaluation the Effect of Chronic Obestatin Therapy on the Serum Glucose, Insulin And Lipid Levels in Type 2 Diabetic Rats
    Safa Al-Halbouni, Shadi Homsi, Nabil koshji
    The Open Public Health Journal.2023;[Epub]     CrossRef
  • Supplementation with a New Standardized Extract of Green and Black Tea Exerts Antiadipogenic Effects and Prevents Insulin Resistance in Mice with Metabolic Syndrome
    Mario De la Fuente-Muñoz, María De la Fuente-Fernández, Marta Román-Carmena, Sara Amor, María C. Iglesias-de la Cruz, Guillermo García-Laínez, Silvia Llopis, Patricia Martorell, David Verdú, Eva Serna, Ángel L. García-Villalón, Sonia I. Guilera, Antonio M
    International Journal of Molecular Sciences.2023; 24(10): 8521.     CrossRef
  • The effect of green tea supplementation on the anthropometric outcomes in overweight and obese women: a time and dose-response meta-analysis of randomized controlled trials
    Yiyi Zhang, Nie Tang, Wei Xia, Shaikh Sanjid Seraj, Marcos Pereira, Periyannan Velu, Hui Zhou, Hanshu Yang, Guanggang Du
    Critical Reviews in Food Science and Nutrition.2023; : 1.     CrossRef
  • Ampelopsis grossedentata improves type 2 diabetes mellitus through modulating the gut microbiota and bile acid metabolism
    Yu-li Hu, Mei Li, Lei Ding, Chuan Peng, You Wu, Wei Liu, Dan Zhao, Ling-ling Qin, Xiang-yu Guo, Li-li Wu, Tong-hua Liu
    Journal of Functional Foods.2023; 107: 105622.     CrossRef
  • Green Tea and Decaffeinated Light Roasted Green Coffee Extract Combination Improved Cardiac Insulin Resistance through Free Fatty Acids and Adiponectin/FAS Pathways Amelioration in Metabolic Syndrome Rat Model
    Mifetika Lukitasari, Mohammad Saifur Rohman, Dwi Adi Nugroho, Mukhamad Nur Kholis, Nila Aisyah Wahyuni, Nashi Widodo
    F1000Research.2023; 10: 990.     CrossRef
  • Impact of Polyphenols on Inflammatory and Oxidative Stress Factors in Diabetes Mellitus: Nutritional Antioxidants and Their Application in Improving Antidiabetic Therapy
    Michal Krawczyk, Izabela Burzynska-Pedziwiatr, Lucyna A. Wozniak, Malgorzata Bukowiecka-Matusiak
    Biomolecules.2023; 13(9): 1402.     CrossRef
  • Research progress on the antidiabetic activities of tea and its bioactive components
    Jianjian Gao, Dan Chen, Zhiyuan Lin, Jiakun Peng, Shuai Yu, Chuang Zhou, Huimin Jiang, Ruofan Sun, Zhi Lin, Weidong Dai
    Beverage Plant Research.2023;[Epub]     CrossRef
  • Identifying Glucose Metabolism Status in Nondiabetic Japanese Adults Using Machine Learning Model with Simple Questionnaire
    Tomoki Uchida, Takeshi Kanamori, Takanori Teramoto, Yuji Nonaka, Hiroki Tanaka, Satoshi Nakamura, Norihito Murayama, Rajesh Kaluri
    Computational and Mathematical Methods in Medicine.2022; 2022: 1.     CrossRef
  • Potential Bioactive Components and Health Promotional Benefits of Tea (Camellia sinensis)
    Saptadip Samanta
    Journal of the American Nutrition Association.2022; 41(1): 65.     CrossRef
  • A Mendelian Randomization Study of the Effect of Tea Intake on Type 2 Diabetes
    Yanan Zhang, Ruiqing Wang, Xinhua Tang, Yanjun Wang, Ping Guo, Shukang Wang, Jing Liu
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • Dietary Supplements for Weight Management: A Narrative Review of Safety and Metabolic Health Benefits
    Eunice Mah, Oliver Chen, DeAnn J. Liska, Jeffrey B. Blumberg
    Nutrients.2022; 14(9): 1787.     CrossRef
  • Antioxidative, Anti-Inflammatory, Anti-Obesogenic, and Antidiabetic Properties of Tea Polyphenols—The Positive Impact of Regular Tea Consumption as an Element of Prophylaxis and Pharmacotherapy Support in Endometrial Cancer
    Piotr Olcha, Anna Winiarska-Mieczan, Małgorzata Kwiecień, Łukasz Nowakowski, Andrzej Miturski, Andrzej Semczuk, Bożena Kiczorowska, Krzysztof Gałczyński
    International Journal of Molecular Sciences.2022; 23(12): 6703.     CrossRef
  • Herbal tea, a novel adjuvant therapy for treating type 2 diabetes mellitus: A review
    Xiangyuan Zhang, Lili Zhang, Boxun Zhang, Ke Liu, Jun Sun, Qingwei Li, Linhua Zhao
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Green tea and cancer and cardiometabolic diseases: a review of the current epidemiological evidence
    Sarah Krull Abe, Manami Inoue
    European Journal of Clinical Nutrition.2021; 75(6): 865.     CrossRef
  • Green and white teas as health-promoting foods
    Daniel Hinojosa-Nogueira, Sergio Pérez-Burillo, Silvia Pastoriza de la Cueva, José Ángel Rufián-Henares
    Food & Function.2021; 12(9): 3799.     CrossRef
  • A systematic review and meta-analysis of association between brain-derived neurotrophic factor and type 2 diabetes and glycemic profile
    Milad Davarpanah, Nafiseh Shokri-mashhadi, Rahele Ziaei, Parvane Saneei
    Scientific Reports.2021;[Epub]     CrossRef
  • Maltodextrin encapsulation improves thermal and pH stability of green tea extract catechins
    Aimara V. De La Cruz‐Molina, Jesus F. Ayala Zavala, Ariadna T. Bernal Mercado, Manuel R. Cruz Valenzuela, Gustavo A. González‐Aguilar, Jaime Lizardi‐Mendoza, Francisco Brown‐Bojorquez, Brenda A. Silva‐Espinoza
    Journal of Food Processing and Preservation.2021;[Epub]     CrossRef
  • Camellia sinensis in Dentistry: Technological Prospection and Scientific Evidence
    Lídia Audrey Rocha Valadas, Rosueti Diógenes de Oliveira Filho, Edilson Martins Rodrigues Neto, Mary Anne Medeiros Bandeira, Marta Maria de França Fonteles, Vanara Florêncio Passos, Ana Cristina de Mello Fiallos, Mara Assef Leitao Lotif, Nara Juliana Cust
    Evidence-Based Complementary and Alternative Medicine.2021; 2021: 1.     CrossRef
  • A comprehensive insight into effects of green tea extract in polycystic ovary syndrome: a systematic review
    Vahid Maleki, Ehsaneh Taheri, Parisa Varshosaz, Fatemeh Pourteymour Fard Tabrizi, Jalal Moludi, Hamed Jafari-Vayghan, Mahdi Shadnoush, Seyed Hossein Yahyazadeh Jabbari, Mehri Seifoleslami, Mohammad Alizadeh
    Reproductive Biology and Endocrinology.2021;[Epub]     CrossRef
  • Green Tea and Decaffeinated Light Roasted Green Coffee Extract Combination Improved Cardiac Insulin Resistance through Free Fatty Acids and Adiponectin/FAS Pathway Amelioration in Metabolic Syndrome Rat Model
    Mifetika Lukitasari, Mohammad Saifur Rohman, Dwi Adi Nugroho, Mukhamad Nur Kholis, Nila Aisyah Wahyuni, Nashi Widodo
    F1000Research.2021; 10: 990.     CrossRef
  • Mechanisms Underlying the Antidiabetic Activities of Polyphenolic Compounds: A Review
    Tina Nie, Garth J. S. Cooper
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Green tea and selenium-enriched green tea ameliorates non-alcoholic fatty liver disease through peripheral 5-hydroxytryptamine signals in high-fat diet-fed mice
    Lin Zhang, Jia-Ying Xu, Ya-Fang Du, Zhang-Min Wang, Jian-Xiang Li, N. Ou-Yang, Yan Wang, Xue-Bin Yin, Li-Qiang Qin
    International Food Research Journal.2021; 28(5): 996.     CrossRef
  • Green Tea Consumption May Be Associated with Cardiovascular Disease Risk and Nonalcoholic Fatty Liver Disease in Type 2 Diabetics: A Cross-Sectional Study in Southeast China
    Huan-Huan Yang, Hui Zhou, Wan-Zhan Zhu, Cai-Long Chen, Guo-Chong Chen, Lu-Gang Yu, Li-Qiang Qin
    Journal of Medicinal Food.2020; 23(10): 1120.     CrossRef
  • The effect of green coffee extract supplementation on lipid profile: A systematic review of clinical trial and in-vivo studies
    Omid Nikpayam, Amir Hossein Faghfouri, Omid Mohammad Tavakoli-Rouzbehani, Seyyed-Mostafa Jalali, Marziyeh Najafi, Golbon Sohrab
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(5): 1521.     CrossRef
  • Biological fates of tea polyphenols and their interactions with microbiota in the gastrointestinal tract: implications on health effects
    Tingting Chen, Chung S. Yang
    Critical Reviews in Food Science and Nutrition.2020; 60(16): 2691.     CrossRef
  • Effects of Timing of Acute and Consecutive Catechin Ingestion on Postprandial Glucose Metabolism in Mice and Humans
    Masaki Takahashi, Mamiho Ozaki, Miku Tsubosaka, Hyeon-Ki Kim, Hiroyuki Sasaki, Yuji Matsui, Masanobu Hibi, Noriko Osaki, Masashi Miyashita, Shigenobu Shibata
    Nutrients.2020; 12(2): 565.     CrossRef
  • Green tea (Camellia sinensis) for the prevention of cancer
    Tommaso Filippini, Marcella Malavolti, Francesca Borrelli, Angelo A Izzo, Susan J Fairweather-Tait, Markus Horneber, Marco Vinceti
    Cochrane Database of Systematic Reviews.2020;[Epub]     CrossRef
  • Metabolic Impact of Flavonoids Consumption in Obesity: From Central to Peripheral
    Viviana Sandoval, Hèctor Sanz-Lamora, Giselle Arias, Pedro F. Marrero, Diego Haro, Joana Relat
    Nutrients.2020; 12(8): 2393.     CrossRef
  • Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallate
    Amir M. Al Hroob, Mohammad H. Abukhalil, Omnia E. Hussein, Ayman M. Mahmoud
    Biomedicine & Pharmacotherapy.2019; 109: 2155.     CrossRef
  • Effects and Mechanisms of Tea for the Prevention and Management of Diabetes Mellitus and Diabetic Complications: An Updated Review
    Jin-Ming Meng, Shi-Yu Cao, Xin-Lin Wei, Ren-You Gan, Yuan-Feng Wang, Shu-Xian Cai, Xiao-Yu Xu, Pang-Zhen Zhang, Hua-Bin Li
    Antioxidants.2019; 8(6): 170.     CrossRef
  • Improvement in fasting blood sugar, anthropometric measurement and hs-CRP after consumption of epigallocatechin-3-gallate (EGCG) in patients with type 2 diabetes mellitus
    Said Hadi, Meysam Alipour, Vahideh Aghamohammadi, Sahar Shahemi, Fatemeh Ghafouri-Taleghani, Niloufar Pourjavidi, Mona Foroughi, Mackaan Chraqipoor
    Nutrition & Food Science .2019; 50(2): 348.     CrossRef
  • The Phosphorylation of IRS1S307 and AktS473 Molecules in Insulin‐Resistant C2C12 Cells Induced with Palmitate Is Influenced by Epigallocatechin Gallate from Green Tea
    Salar Bakhtiyari, Motahareh Zaherara, Karimeh Haghani, Mehrdad Khatami, Ali Rashidinejad
    Lipids.2019; 54(2-3): 141.     CrossRef
  • Effect of annatto-extracted tocotrienols and green tea polyphenols on glucose homeostasis and skeletal muscle metabolism in obese male mice
    Eunhee Chung, Salvatore N. Campise, Hayli E. Joiner, Michael D. Tomison, Gurvinder Kaur, Jannette M. Dufour, Lillian Cole, Latha Ramalingam, Naima Moustaid-Moussa, Chwan-Li Shen
    The Journal of Nutritional Biochemistry.2019; 67: 36.     CrossRef
  • Studies on the Prevention of Cancer and Cardiometabolic Diseases by Tea: Issues on Mechanisms, Effective Doses, and Toxicities
    Chung S. Yang, Jinsong Zhang
    Journal of Agricultural and Food Chemistry.2019; 67(19): 5446.     CrossRef
  • Salvianolic acid B plays an anti-obesity role in high fat diet-induced obese mice by regulating the expression of mRNA, circRNA, and lncRNA
    Tian An, Jing Zhang, Bohan Lv, Yufei Liu, Jiangpinghao Huang, Juan Lian, Yanxiang Wu, Sihua Gao, Guangjian Jiang
    PeerJ.2019; 7: e6506.     CrossRef
  • Popular functional foods and herbs for the management of type-2-diabetes mellitus: A comprehensive review with special reference to clinical trials and its proposed mechanism
    Kamesh Venkatakrishnan, Hui-Fang Chiu, Chin-Kun Wang
    Journal of Functional Foods.2019; 57: 425.     CrossRef
  • Green Tea Polyphenols Modify the Gut Microbiome in db/db Mice as Co‐Abundance Groups Correlating with the Blood Glucose Lowering Effect
    Tingting Chen, Anna B. Liu, Shili Sun, Nadim J. Ajami, Matthew C. Ross, Hong Wang, Le Zhang, Kenneth Reuhl, Koichi Kobayashi, Janet C. Onishi, Liping Zhao, Chung S. Yang
    Molecular Nutrition & Food Research.2019;[Epub]     CrossRef
  • Effect of herbal tea on glycemic control in patients with type 2 diabetes
    Boxun Zhang, Rensong Yue, Xiaoying Huang, Ying Wang, Yayi Jiang, Jiawei Chin
    Medicine.2019; 98(50): e18346.     CrossRef
  • Effects of polysaccharides and polyphenolics fractions of Zijuan tea (Camellia sinensis var. kitamura) on α‐glucosidase activity and blood glucose level and glucose tolerance of hyperglycaemic mice
    Dejing Chen, Jingyuan Sun, Weixue Dong, Yixiao Shen, Zhimin Xu
    International Journal of Food Science & Technology.2018; 53(10): 2335.     CrossRef
  • Green tea consumption reduces apelin and orexin-A in overweight and obese women with different training modalities
    Rahman Soori, Azadeh Safei, Parisa Pournemati, Amine Ghram
    Sport Sciences for Health.2018; 14(2): 421.     CrossRef
  • Green tea consumption and risk of type 2 diabetes in Chinese adults: the Shanghai Women’s Health Study and the Shanghai Men’s Health Study
    Xiaona Liu, Wanghong Xu, Hui Cai, Yu-Tang Gao, Honglan Li, Bu-Tian Ji, Xiang Shu, Thomas Wang, Robert E Gerszten, Wei Zheng, Yong-Bing Xiang, Xiao-Ou Shu
    International Journal of Epidemiology.2018; 47(6): 1887.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer